{"id":37746,"date":"2025-07-22T15:32:16","date_gmt":"2025-07-22T07:32:16","guid":{"rendered":"https:\/\/flcube.com\/?p=37746"},"modified":"2025-07-22T15:32:17","modified_gmt":"2025-07-22T07:32:17","slug":"astrazeneca-to-invest-50-billion-in-us-manufacturing-and-rd-expansion-by-2030","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37746","title":{"rendered":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030"},"content":{"rendered":"\n

UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN<\/a>) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company’s goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.<\/p>\n\n\n\n

Virginia API Facility<\/strong>
Central to this investment is the construction of a new multibillion-dollar active pharmaceutical ingredient (API) facility in Virginia\u2014the largest single manufacturing investment in the company’s global history. The site will produce key ingredients for AstraZeneca’s innovative portfolio in metabolism and weight management, including oral GLP-1, baxdrostat, oral PCSK9, and small molecule combination therapies. The facility will support diverse modalities such as small molecules, peptides, and oligonucleotides, and will incorporate AI, automation, and data analytics to enhance manufacturing efficiency.<\/p>\n\n\n\n

Expansion Across Multiple States<\/strong>
In addition to the Virginia site, AstraZeneca will expand R&D and manufacturing facilities in Maryland, Massachusetts, California, Indiana, and Texas, further strengthening its U.S. operations.<\/p>\n\n\n\n

Current US Operations and Economic Impact<\/strong>
Currently, AstraZeneca operates 19 R&D, manufacturing, and commercial facilities across the United States, employing over 18,000 people and supporting more than 92,000 direct and indirect jobs. In 2024, the company contributed $5 billion directly to the U.S. economy, generating an estimated total economic impact of $20 billion.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by…<\/p>\n","protected":false},"author":1,"featured_media":37748,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,871],"class_list":["post-37746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astrazeneca","tag-az","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37746\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030\" \/>\n<meta property=\"og:description\" content=\"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37746\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T07:32:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-22T07:32:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030\",\"datePublished\":\"2025-07-22T07:32:16+00:00\",\"dateModified\":\"2025-07-22T07:32:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746\"},\"wordCount\":232,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2209.webp\",\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37746#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37746\",\"name\":\"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2209.webp\",\"datePublished\":\"2025-07-22T07:32:16+00:00\",\"dateModified\":\"2025-07-22T07:32:17+00:00\",\"description\":\"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37746\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2209.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2209.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37746#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030 - Insight, China's Pharmaceutical Industry","description":"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37746","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030","og_description":"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.","og_url":"https:\/\/flcube.com\/?p=37746","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-22T07:32:16+00:00","article_modified_time":"2025-07-22T07:32:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37746#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37746"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030","datePublished":"2025-07-22T07:32:16+00:00","dateModified":"2025-07-22T07:32:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37746"},"wordCount":232,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37746#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","keywords":["AstraZeneca","AZ","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37746#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37746","url":"https:\/\/flcube.com\/?p=37746","name":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37746#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37746#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","datePublished":"2025-07-22T07:32:16+00:00","dateModified":"2025-07-22T07:32:17+00:00","description":"UK-based AstraZeneca\u00a0(AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by 2030 to expand its pharmaceutical manufacturing and R&D footprint. This initiative supports the company's goal of reaching $80 billion in total revenue by 2030, with approximately 50% expected to come from the U.S. market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37746#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37746"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37746#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","width":1080,"height":608,"caption":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37746#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2209.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37746"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37746\/revisions"}],"predecessor-version":[{"id":37749,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37746\/revisions\/37749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37748"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}